Robert Freedman, Amanda Rose and Ran Ben-Tzur are partners at Fenwick & West LLP. This post is based on a Fenwick memorandum by Mr. Freedman, Ms. Rose, Mr. Ben-Tzur, and James D. Evans.
A Record-Breaking First Half of 2021
Technology and life sciences companies continued to go public at an extraordinary rate in the first half of 2021 via initial public offerings, de-SPAC mergers and direct listings.
IPOs
IPOs outpaced the second half of 2020, which was previously the most active six months for the space since we began tracking in 2012. In H1 2021, there were 76 technology and 66 life sciencescompany IPOs in the U.S., compared to 48 and 65 in the second half of 2020, respectively.
With 32 IPOs in Q1 and 44 in Q2, technology IPO momentum built throughout the first half of the year. Life sciences offerings increased slightly throughout the first half of the year, with 31 IPOs in Q1 and 35 in Q2, still by far exceeding H1 2020 and several prior years’ offerings.
Mega offerings marked the first half of the year, with 17 companies raising proceeds of more than $1 billion, including one life sciences IPO. Technology IPOs saw deal sizes increase generally. Approximately 93% of IPOs raised more than $100 million in the first half of 2021, versus only 83% in
the second half of 2020. Almost 21% of tech IPOs raised more than $1 billion in H1, the same as the second half of 2020.

